[Click eStock] "Curexo, Earnings Recovery Expected"

NH Investment & Securities expected on the 14th that Curexo could achieve a performance recovery and stock price rebound this year.

Researcher Kang Kyung-geun of NH Investment & Securities explained, "Thanks to exports, the medical robot business will enter a growth trajectory this year," adding, "Due to the strike by medical residents, the cumulative number of domestic robot sales in the third quarter of last year was only eight."

He continued, "Normalization of domestic sales will take time," but added, "Exports, which account for about 70% of sales, are expected to recover significantly starting this year."

He emphasized, "Supply to Southeast Asia and Taiwan will begin," and "Medical robot sales this year are expected to reach 45.3 billion KRW, an increase of 155.0% compared to last year."

Researcher Kang analyzed, "Stable implant distribution and trade business will be complemented by the recovery of medical robots," and "Sales are estimated to reach 85 billion KRW and operating profit 3.1 billion KRW this year." He forecasted that sales will increase by 62.6% compared to last year and operating profit will turn positive.

He said, "Last year, the stock price fell by 65.3% compared to the beginning of the year due to poor performance," and "We expect a stock price rebound following a full-scale performance recovery."

This content was produced with the assistance of AI translation services.